Effect of vasopressin administration and deficiency upon 3H-AVP binding sites in the CNS and periphery during development

P. Szot, K. M. Myers, Daniel Dorsa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Arginine8-vasopressin (AVP, 40 μg/100 g b.wt., SC) was administered to male Long-Evans (LE) pups from day 1 to 7 of life and the pups were sacrificed on day 8 or 60. 3H-AVP binding was performed on membranes prepared from the liver, kidney, and septum. No significant changes were observed in the kidney or septum of animals 8 or 60 days old. However, the chronic AVP treatment did result in a significant increase in the density of 3H-AVP binding sites in the liver when compared to control day 8 pups (control 44 ± 2 vs. AVP 56 ± 3 fmol/mg protein), with no change in affinity. This effect was maintained into adulthood, as the day 60 AVP-treated LE rats also showed a significant increase in liver 3H-AVP binding sites compared to control (control 186 ± 9 vs. AVP 239 ± 14 fmol/mg protein), with no change in affinity. A comparison of 3H-AVP binding sites in 8-day-old LE, heterozygous Brattleboro (HET-BB), and homozygous Brattleboro rats (HOM-BB) was performed to assess the effect of complete (HOM-BB) and partial (HET-BB) VP deficiency on binding sites in the CNS and periphery. The liver again was the only tissue in which a change in 3H-AVP binding characteristics was noted. The HOM-BB rat (Bmax 144 ± 6 fmol/mg protein) displayed a significant increase in AVP binding sites from the LE rat (Bmax 100 ± 7 fmol/mg protein), while the 3H-AVP binding sites in the HET-BB rat liver (Bmax 69.8 ± 9 fmol/mg protein) were significantly lower than LE rats. Thus hepatic AVP receptors appear most sensitive to the presence or absence of vasopressin during the early postnatal period.

Original languageEnglish (US)
Pages (from-to)389-394
Number of pages6
JournalPeptides
Volume13
Issue number2
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Neurogenic Diabetes Insipidus
Vasopressins
Brattleboro Rats
Rats
Binding Sites
Long Evans Rats
Liver
Proteins
Kidney
Animals
Membranes
Tissue

Keywords

  • Brattleboro
  • Chronic AVP
  • Liver
  • Postnatal
  • Receptors

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Effect of vasopressin administration and deficiency upon 3H-AVP binding sites in the CNS and periphery during development. / Szot, P.; Myers, K. M.; Dorsa, Daniel.

In: Peptides, Vol. 13, No. 2, 1992, p. 389-394.

Research output: Contribution to journalArticle

@article{5b4b22a6e3294032b751ac05acd72146,
title = "Effect of vasopressin administration and deficiency upon 3H-AVP binding sites in the CNS and periphery during development",
abstract = "Arginine8-vasopressin (AVP, 40 μg/100 g b.wt., SC) was administered to male Long-Evans (LE) pups from day 1 to 7 of life and the pups were sacrificed on day 8 or 60. 3H-AVP binding was performed on membranes prepared from the liver, kidney, and septum. No significant changes were observed in the kidney or septum of animals 8 or 60 days old. However, the chronic AVP treatment did result in a significant increase in the density of 3H-AVP binding sites in the liver when compared to control day 8 pups (control 44 ± 2 vs. AVP 56 ± 3 fmol/mg protein), with no change in affinity. This effect was maintained into adulthood, as the day 60 AVP-treated LE rats also showed a significant increase in liver 3H-AVP binding sites compared to control (control 186 ± 9 vs. AVP 239 ± 14 fmol/mg protein), with no change in affinity. A comparison of 3H-AVP binding sites in 8-day-old LE, heterozygous Brattleboro (HET-BB), and homozygous Brattleboro rats (HOM-BB) was performed to assess the effect of complete (HOM-BB) and partial (HET-BB) VP deficiency on binding sites in the CNS and periphery. The liver again was the only tissue in which a change in 3H-AVP binding characteristics was noted. The HOM-BB rat (Bmax 144 ± 6 fmol/mg protein) displayed a significant increase in AVP binding sites from the LE rat (Bmax 100 ± 7 fmol/mg protein), while the 3H-AVP binding sites in the HET-BB rat liver (Bmax 69.8 ± 9 fmol/mg protein) were significantly lower than LE rats. Thus hepatic AVP receptors appear most sensitive to the presence or absence of vasopressin during the early postnatal period.",
keywords = "Brattleboro, Chronic AVP, Liver, Postnatal, Receptors",
author = "P. Szot and Myers, {K. M.} and Daniel Dorsa",
year = "1992",
doi = "10.1016/0196-9781(92)90126-N",
language = "English (US)",
volume = "13",
pages = "389--394",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of vasopressin administration and deficiency upon 3H-AVP binding sites in the CNS and periphery during development

AU - Szot, P.

AU - Myers, K. M.

AU - Dorsa, Daniel

PY - 1992

Y1 - 1992

N2 - Arginine8-vasopressin (AVP, 40 μg/100 g b.wt., SC) was administered to male Long-Evans (LE) pups from day 1 to 7 of life and the pups were sacrificed on day 8 or 60. 3H-AVP binding was performed on membranes prepared from the liver, kidney, and septum. No significant changes were observed in the kidney or septum of animals 8 or 60 days old. However, the chronic AVP treatment did result in a significant increase in the density of 3H-AVP binding sites in the liver when compared to control day 8 pups (control 44 ± 2 vs. AVP 56 ± 3 fmol/mg protein), with no change in affinity. This effect was maintained into adulthood, as the day 60 AVP-treated LE rats also showed a significant increase in liver 3H-AVP binding sites compared to control (control 186 ± 9 vs. AVP 239 ± 14 fmol/mg protein), with no change in affinity. A comparison of 3H-AVP binding sites in 8-day-old LE, heterozygous Brattleboro (HET-BB), and homozygous Brattleboro rats (HOM-BB) was performed to assess the effect of complete (HOM-BB) and partial (HET-BB) VP deficiency on binding sites in the CNS and periphery. The liver again was the only tissue in which a change in 3H-AVP binding characteristics was noted. The HOM-BB rat (Bmax 144 ± 6 fmol/mg protein) displayed a significant increase in AVP binding sites from the LE rat (Bmax 100 ± 7 fmol/mg protein), while the 3H-AVP binding sites in the HET-BB rat liver (Bmax 69.8 ± 9 fmol/mg protein) were significantly lower than LE rats. Thus hepatic AVP receptors appear most sensitive to the presence or absence of vasopressin during the early postnatal period.

AB - Arginine8-vasopressin (AVP, 40 μg/100 g b.wt., SC) was administered to male Long-Evans (LE) pups from day 1 to 7 of life and the pups were sacrificed on day 8 or 60. 3H-AVP binding was performed on membranes prepared from the liver, kidney, and septum. No significant changes were observed in the kidney or septum of animals 8 or 60 days old. However, the chronic AVP treatment did result in a significant increase in the density of 3H-AVP binding sites in the liver when compared to control day 8 pups (control 44 ± 2 vs. AVP 56 ± 3 fmol/mg protein), with no change in affinity. This effect was maintained into adulthood, as the day 60 AVP-treated LE rats also showed a significant increase in liver 3H-AVP binding sites compared to control (control 186 ± 9 vs. AVP 239 ± 14 fmol/mg protein), with no change in affinity. A comparison of 3H-AVP binding sites in 8-day-old LE, heterozygous Brattleboro (HET-BB), and homozygous Brattleboro rats (HOM-BB) was performed to assess the effect of complete (HOM-BB) and partial (HET-BB) VP deficiency on binding sites in the CNS and periphery. The liver again was the only tissue in which a change in 3H-AVP binding characteristics was noted. The HOM-BB rat (Bmax 144 ± 6 fmol/mg protein) displayed a significant increase in AVP binding sites from the LE rat (Bmax 100 ± 7 fmol/mg protein), while the 3H-AVP binding sites in the HET-BB rat liver (Bmax 69.8 ± 9 fmol/mg protein) were significantly lower than LE rats. Thus hepatic AVP receptors appear most sensitive to the presence or absence of vasopressin during the early postnatal period.

KW - Brattleboro

KW - Chronic AVP

KW - Liver

KW - Postnatal

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=0026719784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026719784&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(92)90126-N

DO - 10.1016/0196-9781(92)90126-N

M3 - Article

VL - 13

SP - 389

EP - 394

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 2

ER -